Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
January 28th, 2019 by Christian Schmidl
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL, Published online: 28 January 2019; doi:10.1038/s41589-018-0205-2
Epigenome profiling in combination with imaging-based chemosensitivity and integrative bioinformatic analysis establishes a method for detecting therapy-induced vulnerabilities, as shown here for ibrutinib-treated chronic lymphocytic leukemia.